Ahobil Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 23-05-2024
- Paid Up Capital ₹ 0.10 M
as on 23-05-2024
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2022
About Ahobil Life Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Krishnan Eswaran and Sivakumar Rajagopalan serve as directors at the Company.
- CIN/LLPIN
U33110MH2021PTC360745
- Company No.
360745
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 May 2021
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ahobil Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishnan Eswaran  | Director | 19-Mar-2022 | Current |
| Sivakumar Rajagopalan | Director | 20-May-2021 | Current |
Financial Performance of Ahobil Life Sciences.
Enhance accessibility to Ahobil Life Sciences's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Ahobil Life Sciences?
Unlock access to Ahobil Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Opel Systems And Consultants Private LimitedActive 26 years 6 monthsSivakumar Rajagopalan is a mutual person
- Ifet Global Ventures Private LimitedActive 2 months 23 days
Sivakumar Rajagopalan is a mutual person
- Mobile Erp Solutions Private LimitedActive 16 years 9 months
Sivakumar Rajagopalan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ahobil Life Sciences?
Ahobil Life Sciences has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ahobil Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ahobil Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
